A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer

Lung Cancer. 2020 Jul:145:33-39. doi: 10.1016/j.lungcan.2020.04.028. Epub 2020 Apr 28.

Abstract

Objectives: We evaluated the prognostic impact of the presence of ground glass opacity (GGO) component and compared a modified clinical T categorization (cTm) with the current 8th classification (cT8) for survival prediction in Chinese patients with clinical stage I non-small cell lung cancer (NSCLC).

Methods: According to cTm and cT8 classifications, we retrospectively evaluated 1461 patients with part-solid or pure-solid lesions. The recurrence-free survival (RFS) and overall survival (OS) were analyzed by Kaplan-Meier method and Cox proportional hazard model. The concordance index (C- index), reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA) were performed to estimate reclassification net benefits of cTm for survival prediction.

Results: The cT8 classification clearly stratifies the survival outcomes in solid tumors but not in part-solid tumors. The presence of GGO components was an independent prognostic factor for both RFS and OS (p < 0.001), indicating a better outcome in each clinical T stage. The C-index was significantly improved from 0.650 to 0.730 for RFS (p < 0.001) and 0.647 to 0.730 for OS (p < 0.001) after reclassifying by cTm categorization. The DCA, NRI (RFS: 0.342, OS: 0.302), and IDI (RFS: 0.070, OS: 0.054) demonstrated that the cTm classification provided more net benefit in the survival prediction compared with the current cT8 classification.

Conclusions: The current cT8 classification may not be appropriate for part-solid lesions because the presence of GGO components is associated with excellent prognosis despite clinical stage. Also, the cTm classification for part-solid lesions showed an improvement in survival prediction.

Keywords: Ground glass opacity; Non–small cell lung cancer; Survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / pathology
  • China / epidemiology
  • Humans
  • Lung Neoplasms* / pathology
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies